Document Detail


New antibacterials for the treatment of toxoplasmosis; a patent review.
MedLine Citation:
PMID:  22404108     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Toxoplasma gondii is an opportunistic protozoan parasite responsible for toxoplasmosis. T. gondii is able to infect a wide range of hosts, particularly humans and warm-blooded animals. Toxoplasmosis can be considered as one of the most prevalent parasitic diseases affecting close to one billion people worldwide, but its current chemotherapy is still deficient and is only effective in the acute phase of the disease.
AREAS COVERED: This review covers different approaches to toxoplasmosis chemotherapy focused on the metabolic differences between the host and the parasite. Selective action on different targets such as the isoprenoid pathway, dihydrofolate reductase, T. gondii adenosine kinase, different antibacterials, T. gondii histone deacetylase and calcium-dependent protein kinases is discussed.
EXPERT OPINION: A new and safe chemotherapy is needed, as T. gondii causes serious morbidity and mortality in pregnant women and immunodeficient patients undergoing chemotherapy. A particular drawback of the available treatments is the lack of efficacy against the tissue cyst of the parasite. During this review a broad scope of several attractive targets for drug design have been presented. In this context, the isoprenoid pathway, dihydrofolate reductase, T. gondii histone deacetylase are promising molecular targets.
Authors:
Juan Bautista Rodriguez; Sergio Hernán Szajnman
Related Documents :
22635078 - The di bella method (dbm) improved survival, objective response and performance status ...
19697088 - Prognostic effect of diaphyseal location in osteosarcoma: a cohort case-control study a...
17472558 - Clinical and immunohistochemical differentiation of gastrointestinal stromal tumors fro...
16860938 - Primary bone osteosarcoma in the pediatric age: state of the art.
2464818 - Feulgen dna values in wilms' tumour in relation to prognosis.
9830438 - A 2-week pretreatment with 13-cis-retinoic acid + interferon-alpha-2a prior to definiti...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2012-03-10
Journal Detail:
Title:  Expert opinion on therapeutic patents     Volume:  22     ISSN:  1744-7674     ISO Abbreviation:  Expert Opin Ther Pat     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-03-14     Completed Date:  2012-07-03     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  9516419     Medline TA:  Expert Opin Ther Pat     Country:  England    
Other Details:
Languages:  eng     Pagination:  311-33     Citation Subset:  IM    
Affiliation:
Universidad de Buenos Aires, Química Orgánica & UMYMFOR (CONICET-FCEyN), Facultad de Ciencias Exactas y Naturales, Pab 2, Ciudad Universitaria, Buenos Aires, C1428EHA, Argentina. jbr@qo.fcen.uba.ar
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antiprotozoal Agents / adverse effects,  pharmacology*
Drug Design
Female
Humans
Immunocompromised Host
Molecular Targeted Therapy*
Patents as Topic
Pregnancy
Toxoplasma / isolation & purification
Toxoplasmosis / drug therapy*,  epidemiology,  parasitology
Toxoplasmosis, Animal / drug therapy,  epidemiology,  parasitology
Chemical
Reg. No./Substance:
0/Antiprotozoal Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Aldehyde oxidase functions as a superoxide generating NADH oxidase: an important redox regulated pat...
Next Document:  Arabidopsis Thaliana Histone Deacetylase 14 (Hda14) is an ?-Tubulin Deacetylase that Associates with...